Hot debate over risk of myocarditis puts spotlight on heart disease – PR Newswire | Candle Made Easy News Commentary

PALM BEACH, Fla., July 26, 2022 /PRNewswire/ — As pediatric COVID-19 vaccines meet the Centers for Disease Control and Prevention (CDC) recommendation, concerns that they may increase children’s risk of myocarditis have sparked heated debate. Myocarditis is a rare heart disease that causes inflammation of the heart muscle. Some companies that deal with the world’s biggest health threats such as heart disease are among others Johnson&Johnson (NYSE:JNJ), Takeda Pharmaceutical Co Ltd (NYSE:TAK), Novo Nordisk A/S (NYSE: NVO), Bristol Myers Squibb Co (NYSE:BMY) and Cardioles therapeutics (NASDAQ:CRDL) (TSX:CRDL).


Moderna previously confirmed that the FDA delayed approval of its childhood vaccine due to the risk of myocarditis. The concern came after cases of myocarditis occurring in young men after their second dose of an mRNA vaccine. Acute myocarditis is an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people under 35 years of age. This triggers an alarm and arouses interest in practical treatments.

Before the pandemic, few had heard of myocarditis, but now it’s a serious concern and parents everywhere are discussing it.

Currently, the risk of myocarditis appears to be low, although the debate has drawn public attention to this inflammatory disease.

Nevertheless, in some cases, myocarditis can lead to heart failure, so parents’ concern is justified.

The increase in myocarditis cases could further exacerbate the global problem of heart failure. Not only is it devastating to life, but it also increases the pressure on healthcare providers and is a growing economic burden. According to the CDC, cardiovascular disease (CVD) is the leading cause of death, with more than 800,000 Americans suffering heart attacks annually. Unfortunately, this problem is increasing and is being exacerbated by obesity, diabetes, high blood pressure and now COVID-19.

At a time when heart disease and other global health problems are on the rise, the need for appropriate treatments has never been greater.

At Novo Nordisk, cardiovascular researchers are primarily focused on identifying new ways to treat cardiovascular diseases, particularly atherosclerosis and chronic heart failure. It also develops life-changing diabetes and weight-loss drugs. And Johnson & Johnson is working on treatments for respiratory diseases, which are often associated with heart disease.

Meanwhile, Takeda’s Flexbumin drug is an albumin solution indicated for use in cardiopulmonary bypass surgery. bristolMyers Squibb advances his research on cardiovascular disease, and happily Cardioles therapeutics (NASDAQ:CRDL) (TSX:CRDL) is doing something about myocarditis. This clinical-stage company is focused on the discovery and development of an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular disease. Cardio’s primary focus is the treatment of inflammatory heart disease, particularly acute myocarditis, recurrent pericarditis, and diastolic heart failure.


The Company’s lead product candidate, CardiolRx™, is a pharmaceutically manufactured oral formulation of cannabidiol that is being clinically developed for use in cardiovascular medicine. The pre-clinical data for this is compelling, as it exhibits potent anti-inflammatory and anti-fibrotic properties. It is this data that has prompted so many notables to support these studies and invest in the Cardiol journey.

Overall, there is great excitement about the effectiveness of CardioRx™ in multiple use cases and therefore the potential for the company to benefit from multiple revenue streams in the future. If his drug turns out to be that elusive treatment, it will surely be cause for celebration.

Cardiol is currently conducting a multinational clinical trial and has received IND clearance from the FDA to conduct clinical trials to evaluate the efficacy and safety of CardiolRx™ in two rare disease indications: acute myocarditis and recurrent pericarditis. The multinational, randomized, double-blind, placebo-controlled, phase 2 study of Cardiol in acute myocarditis is scheduled to begin shortly. A multi-centre, open-label, phase 2 pilot study of CardiolRx™ in recurrent pericarditis is planned to be conducted in parallel with the Company’s acute myocarditis study.

As the world faces increasing healthcare challenges, physicians are welcoming potential breakthroughs in the treatment of rare diseases.

Johnson&Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceutica is conducting the Heartline study with Apple to study atrial fibrillation and explore how wearable technology can help people identify atrial fibrillation to reduce the likelihood of adverse health effects.

Takeda Pharmaceutical Co Ltd (NYSE: TAK) is a leader in bleeding disorders. The Company recently signed a 15-year lease with BioMed Realty for the construction of approximately 600,000 square feet of research and development (R&D) and office space. The state-of-the-art facility will enable Takeda, the life sciences’ largest employer, in Massachusettsto create a purpose-built R&D facility featuring labs of the future with modern design elements and enhanced technology to support the company’s efforts to drive innovation for patients. Takeda focuses its R&D efforts in four therapeutic areas: oncology, rare genetics and hematology, neuroscience and gastroenterology (GI). The company is also making targeted R&D investments in plasma-derived therapies and vaccines.

Novo Nordisk A/S (NYSE: NVO) has partnered with Echosens, a high-tech liver diagnostics solutions company. Together, they hope to advance the early detection of nonalcoholic steatohepatitis (NASH) and raise awareness of the disease among patients, healthcare providers and other stakeholders.

Bristol Myers Squibb Co (NYSE: BMY) is evaluating several novel agents to address the needs of patients with severe cardiovascular disease. The company established the Bristol Myers Squibb Foundation to focus on providing social support and services to vulnerable and underfunded populations to both educate and reduce the cost of cardiovascular care.

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates and, is a third-party news distribution service provider that distributes electronic information through multiple online media channels. FNM is in no way affiliated with any of the companies mentioned here. FNM and its affiliates are a news distribution solutions provider and are NOT a registered broker/dealer/analyst/adviser, do not hold investment licenses and are NOT permitted to sell, offer for sale or offer for sale any securities. FNM’s market updates, news stories and company profiles are NOT a solicitation or recommendation to buy, sell or hold any security. The material in this press release is for informational purposes only and should NEVER be construed or interpreted as research material. All readers are strongly advised to do their own research, due diligence and advice from a licensed financial professional before investing any amount in stocks. All materials contained herein are newly released content and details previously distributed by the companies mentioned in this press release. FNM is not responsible for the investment decisions of its readers or subscribers. Investors are reminded that when they invest in equities they may lose all or part of their investment. FNM was remunerated for services rendered on an ongoing basis twenty six hundred dollars for coverage of current Cardiol Therapeutics press releases by an unaffiliated third party. FNM DOES NOT HOLD ANY SHARES OF ANY COMPANY IDENTIFIED IN THIS ANNOUNCEMENT.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”. , “will” or “should”, “expect”, “anticipate”, “draft”, “eventually” or “forecast”. You are cautioned that such statements are subject to a variety of risks and uncertainties that could cause future conditions, events or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected forward-looking statements may differ as a result of various factors and other risks identified in a company’s Annual Report on Form 10-K or 10-KSB and other filings by that company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements contained herein and not place undue reliance on such statements. The forward-looking statements contained in this press release are made as of the date of this release and FNM undertakes no obligation to update such statements.

Media contact:
[email protected]


Leave a Comment